Valuation: Inotiv, Inc.

Market Cap 387K 335K 313K 287K 540K 36.86M 548K 3.67M 1.44M 18.47M 1.45M 1.42M 61.07M P/E 2024
-0.41x
P/E 2025 -0.69x
Enterprise Value 438M 379M 354M 325M 610M 41.68B 620M 4.15B 1.63B 20.89B 1.64B 1.61B 69.06B EV / Sales 2024
0.95x
EV / Sales 2025 0.95x
Free-Float
93.32%
Yield 2024 *
-
Yield 2025 -
1 day-26.00%
1 month-7.50%
3 months-96.23%
6 months-97.35%
Current year-98.03%
1 month 0.01
Extreme 0.011
0.03
Current year 0.01
Extreme 0.007
0.65
1 year 0.01
Extreme 0.007
2.13
3 years 0.01
Extreme 0.007
11.42
5 years 0.01
Extreme 0.007
60.66
10 years 0.01
Extreme 0.007
60.66
Manager TitleAgeSince
Chief Executive Officer 67 2019-01-11
Director of Finance/CFO 61 2020-03-05
Chief Operating Officer 60 2021-02-14
Date Insider Type Main position Quantity % Market Cap.
7/19/26 Others

Chief Executive Officer

-1,361,215 3.9017%
7/19/26 Others

Director

-729,626 2.0913%
7/19/26 Others

Chief Financial Officer

-139,616 0.4002%
Change 5-day change 1-year change 3-year change Capi.($)
-26.00%-.--%-99.43%-99.84% 387K
+0.99%+1.78%+4.07%+16.73% 49.47B
+3.71%+9.40%+486.98%+592.14% 43.61B
+2.70%+1.57%+33.39%+8.85% 39.29B
+5.60%+10.21%+16.76%+85.72% 39.6B
+2.21%+6.75%+21.31%+53.37% 32.43B
+2.23%+4.71% - - 16.84B
+0.97%+2.35%+37.75%+126.84% 16.49B
-0.11%+2.41%+6.24%+18.87% 14.01B
+0.75%+15.04%+78.59%+30.30% 12.77B
Average -0.70%+1.85%+65.07%+92.55% 26.45B
Weighted average by Cap. +2.54%+6.10%+104.25%+140.79%

Financials

2024 2025
Net sales 491M 424M 396M 364M 684M 46.7B 695M 4.65B 1.83B 23.41B 1.84B 1.8B 77.39B 513M 444M 414M 380M 715M 48.83B 726M 4.86B 1.91B 24.47B 1.93B 1.88B 80.9B
Net income -108M -93.8M -87.6M -80.36M -151M -10.32B -154M -1.03B -403M -5.17B -407M -398M -17.1B -68.62M -59.36M -55.43M -50.85M -95.65M -6.53B -97.17M -650M -255M -3.27B -258M -252M -10.82B
Net Debt 424M 366M 342M 314M 591M 40.32B 600M 4.02B 1.58B 20.21B 1.59B 1.56B 66.82B 438M 378M 353M 324M 610M 41.64B 620M 4.15B 1.63B 20.87B 1.64B 1.61B 69B
Logo Inotiv, Inc.
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Employees
1,996
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. NOTVQ Stock